Goldman Sachs
ABEO icon

Goldman Sachs’s Abeona Therapeutics ABEO Stock Holding History

Goldman Sachs’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,516
Closed -$544K – 5618
2018
Q1 		$544K Buy
+1,516
New +$563K ﹤0.01% 4436

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OIA
OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs's ABEO Position: Q2 2026 in Review

Goldman Sachs increased its Abeona Therapeutics (ABEO) stake by 8.3% in Q2 2026, buying an estimated $517K and bringing the position to 1,224,806 shares worth $7.57M. The position accounts for ﹤0.01% of the portfolio, ranked #3504.

Goldman Sachs first reported a position in ABEO in Q4 2015 and has held it in 35 quarters since. 126 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

  • Goldman Sachs held 1,224,806 shares of Abeona Therapeutics worth $7.57M as of Q2 2026.
  • Goldman Sachs bought 94,187 Abeona Therapeutics shares in Q2 2026, an estimated $517K.
  • Abeona Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3504 holding.
  • Goldman Sachs first reported a position in Abeona Therapeutics in Q4 2015 and has held it in 35 quarters since.
  • 126 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.